Products

Meilun Pharmaceutical Group was founded in 1993 and is a modern, diversified, and international high-tech enterprise group mainly engaged in medical, scientific research, manufacturing of traditional Chinese and Western medicine, cultivation and extraction of traditional Chinese medicine, research and production of natural plant cosmetics, real estate development and construction, international trade, and overseas direct sales. The registered capital of the enterprise is 600 million yuan, and the total assets exceed 6 billion yuan. 

Meilun Pharmaceutical Group is an enterprise in Tianjin that undertakes major high-tech industrialization projects. To accelerate development, the group company has invested and established a high-tech industrial park in Tianjin Beichen Economic Development Zone. There are Chinese and Western medicine preparation production workshops, traditional Chinese medicine extraction workshops, drug research institutes, natural plant cosmetics production bases, and cosmetics science and technology research institutes in the park that meet the requirements of national GMP standards. The supporting facilities are complete, which can fully meet the requirements of modern, large-scale, professional, and standardized production.

In order to speed up the internationalization of the Chinese medicine industry, the Group invested hundreds of millions of yuan to build a large-scale and modern demonstration base for the industrialization of Chinese medicine extraction in North China, and build an innovative development platform for the extraction of Chinese medicine standards. The traditional Chinese medicine extraction workshop passed the national GMP quality management certification in 2005, with clear functional areas and high degree of automation. It can produce 10000 tons of various plant extracts annually. Currently, more than 100 standard extracts of traditional Chinese medicine have been developed and widely used in the production of drugs, health products, and cosmetics. Some products have been exported to countries such as Japan and South Africa, achieving good economic and social effects.

The group company attaches great importance to scientific and technological research and development, and has invested heavily in self-developed high-quality steviol glycoside production processes and automatic control systems. Among them, "Research and Industrialization of New Steviol glycoside Deep Processing Processes" was included in the 2010 Tianjin Major Science and Technology Innovation Special Project. At present, the company has been able to produce more than 99% of the total glycosides, more than 95% of the Active ingredient Stevioside A (Reb-A), or more than 95% of the total glycosides, more than 90% of the monomer Stevioside (STV) STV products, with an annual production capacity of 1000 tons, and has passed international certification such as HACCP and BRC. This technology fills the gap in the industrialization of high-purity Reb-A and STV in China, breaking foreign technological monopolies. The group company has become a domestic supplier of high-end steviol glycoside products, with products exported to countries and regions such as the United States, Japan, Australia, Canada, South Korea, and the European Union.

In order to inherit and develop the theoretical practice of traditional Chinese medicine in China, the group relies on the rich medical and pharmaceutical product service advantages of enterprises, leverages the technical talent strength of enterprise industry, academia, and research cooperation, invests in the Muse Lake Scenic Area of Hainan, closely adheres to the policy guidance of Hainan's construction of an international tourism island and vigorously develops the health and cultural industry, striving to create a Silicon Valley of global traditional Chinese medicine culture and technology, Build the Muse Lake Scenic Area into a fragrant island among Hainan's fragrant islands, broaden the concept of Meilun's great health to the world, and lead traditional Chinese medicine to the world.

Innovation is the eternal theme of humanity, and the American people continuously deepen this theme with passion. In the new global economic trend, Meilun Pharmaceutical Group is focusing on cultural